SCHEDULE: Armistice Capital Discloses 9.99% Stake in Dermata

Armistice Capital, LLC and Steven Boyd have disclosed a 9.99% beneficial ownership stake in Dermata Therapeutics, Inc. common stock as of June 30, 2025.

Summary

• Armistice Capital, LLC and Steven Boyd, collectively referred to as the "Reporting Persons," have filed a Schedule 13G.
• The filing indicates beneficial ownership of 672,134 shares of Dermata Therapeutics, Inc. common stock.
• This ownership represents 9.99% of the issuer's common stock class.
• Armistice Capital, LLC, a Delaware entity, serves as the investment manager for Armistice Capital Master Fund Ltd., the direct holder of the shares.
• Steven Boyd, a U.S. citizen, is the managing member of Armistice Capital, LLC.
• The shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Dermata Therapeutics, Inc.

Sentiment

Score: 7

Explanation: The disclosure of a significant beneficial ownership stake by a reputable investment firm is generally viewed as a positive signal, indicating institutional interest and potential confidence in the company's value or future prospects. The filing itself is a routine compliance document.

Positives

• A significant beneficial ownership stake of 9.99% by an institutional investor like Armistice Capital, LLC, and its managing member Steven Boyd, can signal confidence in Dermata Therapeutics, Inc.'s future prospects.
• The acquisition is stated to be in the ordinary course of business, indicating a standard investment rather than an activist position.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding the issuer's financial performance or strategic outlook.

Industry Context

It is common practice for institutional investment firms to disclose significant beneficial ownership stakes in publicly traded companies through Schedule 13G filings, particularly when their holdings reach or exceed 5% of a class of securities. This filing reflects a standard disclosure for an investment manager and its principal.

Stakeholder Impact

• Shareholders may perceive the significant stake by Armistice Capital and Steven Boyd as a positive indicator of institutional confidence in Dermata Therapeutics, Inc., potentially influencing market sentiment.

Key Dates

Recommendation

The disclosure of a significant beneficial ownership stake by Armistice Capital and Steven Boyd in Dermata Therapeutics, Inc. indicates institutional interest and potential confidence in the company's long-term prospects. While this filing itself does not provide operational or financial performance data, a nearly 10% stake suggests a notable investment thesis. Investors should monitor future filings and company performance for further insights, but this filing alone does not warrant a strong buy or sell recommendation without additional fundamental analysis.

Keywords

Dermata Therapeutics, Armistice Capital, Steven Boyd, Schedule 13G, beneficial ownership, common stock, institutional investment, biotechnology, pharmaceuticals